First Quadrant L P CA boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 14.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 634,084 shares of the medical equipment provider’s stock after buying an additional 78,948 shares during the period. First Quadrant L P CA owned about 0.23% of Hologic worth $28,775,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the stock. TrimTabs Asset Management LLC increased its stake in Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock valued at $127,000 after buying an additional 1,408 shares during the last quarter. Advisor Partners LLC purchased a new position in shares of Hologic during the first quarter worth approximately $201,000. Miles Capital Inc. purchased a new position in shares of Hologic during the first quarter worth approximately $206,000. Stratos Wealth Partners LTD. purchased a new position in shares of Hologic during the first quarter worth approximately $210,000. Finally, Affinity Wealth Management purchased a new position in shares of Hologic during the first quarter worth approximately $229,000. Hedge funds and other institutional investors own 94.04% of the company’s stock.
Shares of Hologic, Inc. (NASDAQ HOLX) traded up 0.033% during midday trading on Wednesday, reaching $44.965. The company had a trading volume of 770,289 shares. The stock has a market capitalization of $12.59 billion, a PE ratio of 16.122 and a beta of 0.91. The company’s 50 day moving average price is $44.96 and its 200 day moving average price is $42.66. Hologic, Inc. has a 52-week low of $35.15 and a 52-week high of $46.80.
Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, May 10th. The medical equipment provider reported $0.50 EPS for the quarter, topping the consensus estimate of $0.46 by $0.04. Hologic had a return on equity of 25.26% and a net margin of 27.31%. The company had revenue of $715.40 million for the quarter, compared to analyst estimates of $685.24 million. During the same quarter in the previous year, the company posted $0.47 earnings per share. The firm’s revenue was up 3.2% compared to the same quarter last year. Equities research analysts expect that Hologic, Inc. will post $2.01 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “First Quadrant L P CA Purchases 78,948 Shares of Hologic, Inc. (HOLX)” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2017/07/19/first-quadrant-l-p-ca-purchases-78948-shares-of-hologic-inc-holx.html.
A number of brokerages have commented on HOLX. Stifel Nicolaus boosted their target price on shares of Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, May 11th. Jefferies Group LLC set a $49.00 target price on shares of Hologic and gave the stock a “buy” rating in a report on Sunday, May 28th. Piper Jaffray Companies reiterated a “buy” rating and issued a $51.00 target price on shares of Hologic in a report on Friday, July 14th. Barclays PLC reiterated an “overweight” rating and issued a $53.00 target price (up from $50.00) on shares of Hologic in a report on Monday. Finally, Zacks Investment Research downgraded shares of Hologic from a “hold” rating to a “sell” rating in a report on Wednesday, March 29th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the company. Hologic has a consensus rating of “Buy” and an average target price of $47.77.
In other Hologic news, Director Lawrence M. Levy sold 9,076 shares of Hologic stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $42.80, for a total value of $388,452.80. Following the transaction, the director now directly owns 43,165 shares in the company, valued at approximately $1,847,462. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence M. Levy sold 2,960 shares of Hologic stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $44.54, for a total value of $131,838.40. Following the completion of the transaction, the director now owns 45,634 shares in the company, valued at $2,032,538.36. The disclosure for this sale can be found here. Insiders sold a total of 96,404 shares of company stock worth $4,256,438 over the last quarter. Company insiders own 0.79% of the company’s stock.
About Hologic
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
